Bioceres Crop Solutions Reports Lower Revenue For Q3 2025

Key Takeaways

• Bioceres Crop Solutions reported $60.6 million in total revenue for Q3 FY2025, down from $84.0 million in Q3 FY2024.
• Net cash flow from operating activities reached $23.3 million, up $40.7 million year-over-year.
• Adjusted EBITDA was $9.0 million, reflecting a 57% decrease.
• The company obtained EPA registration for Rinotec, its biological insecticide and nematicide platform.
• Working capital improvements were a major contributor to the quarter’s cash performance.

Bioceres Crop Solutions Reports Lower Revenue, Improved Operating Cash Flow

Bioceres Crop Solutions (NASDAQ: BIOX) released financial results for the third fiscal quarter ended March 31, 2025. The company reported total revenue of $60.6 million, a 28% decrease compared to $84.0 million in the same period last year. The decline was primarily attributed to the absence of a $15.7 million accrual related to Syngenta’s initial downpayment in Q3 FY2024.

Segment results for Q3 FY2025 were as follows:

• Crop Protection: $38.0 million (down 19%)
• Seed and Integrated Products: $10.9 million (up 26%)
• Crop Nutrition: $11.8 million (down 59%)

Gross profit for the quarter was $23.8 million, down from $42.6 million, and gross margin declined from 51% to 39%.

Bioceres Crop Solutions Delivers Positive Cash Flow and Reduces Debt

Despite the revenue decline, Bioceres Crop Solutions reported $23.3 million in net cash flow from operating activities, compared to a negative $17.4 million in Q3 FY2024. The improvement was driven by optimized working capital, including:

• A $30.9 million positive shift in trade and other receivables
• A $13.5 million gain from inventory and biological asset changes

These gains were partially offset by a $20.8 million decrease in trade and other payables.

Adjusted EBITDA for the quarter was $9.0 million, compared to $21.1 million last year. The company also reported a net loss of $1.6 million and operating profit of $0.9 million for the quarter.

Bioceres Crop Solutions Highlights Strategic Shift in Seed Business

During Q3 FY2025, Bioceres Crop Solutions implemented a revised strategy for its seed business. The company exchanged certain non-core traits and intellectual property to streamline royalty obligations and reallocate rights to key traits. These efforts contributed approximately $7.5 million to other income during the quarter.

The company also transferred certain seed production and commercialization activities to customers, resulting in a reduction of operating expenses in the seed segment.

Gains EPA Approval for Rinotec Platform

Bioceres Crop Solutions received U.S. EPA registration for Rinotec, a biological insecticide and nematicide for integrated pest management. The product has also received regulatory approval in Brazil. Rinotec is now positioned to support on-seed and in-field applications in both row and specialty crops.

According to company statements, the Rinotec platform enables broader market access for biological alternatives to synthetic pesticides and aligns with demand for bio-based crop protection tools.

Bioceres Crop Solutions Emphasizes Focus on Working Capital and Biological Portfolio

In remarks from company executives, Bioceres Crop Solutions reaffirmed its strategic focus on optimizing capital allocation, strengthening its biological product portfolio, and improving operational efficiency. The third fiscal quarter reflected a seasonal downturn, yet internal changes and product milestones, including Rinotec’s approval, were noted as significant developments.

Read the complete financial results here.